Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prospective study of interferon therapy for compensated cirrhotic patientswith chronic hepatitis C by monitoring serum hepatitis C RNA
Autore:
Shiratori, Y; Yokosuka, O; Nakata, R; Ihori, M; Hirota, K; Katamoto, T; Unuma, T; Okano, K; Ikeda, Y; Hirano, M; Kawase, T; Takano, S; Matsumoto, K; Ohashi, Y; Omata, M;
Indirizzi:
Univ Tokyo, Dept Internal Med 2, Bunkyo Ku, Tokyo 113, Japan Univ Tokyo Tokyo Japan 113 t Internal Med 2, Bunkyo Ku, Tokyo 113, Japan Chiba Univ, Sch Med, Dept Internal Med 1, Chiba 280, Japan Chiba Univ Chiba Japan 280 ch Med, Dept Internal Med 1, Chiba 280, Japan Japanese Red Cross Med Ctr, Dept Gastroenterol, Tokyo, Japan Japanese Red Cross Med Ctr Tokyo Japan Dept Gastroenterol, Tokyo, Japan Mito Saiseikai Hosp, Dept Gastroenterol, Ibaraki, Osaka, Japan Mito Saiseikai Hosp Ibaraki Osaka Japan roenterol, Ibaraki, Osaka, Japan JR Tokyo Gen Hosp, Dept Gastroenterol, Tokyo, Japan JR Tokyo Gen Hosp Tokyo Japan en Hosp, Dept Gastroenterol, Tokyo, Japan Mitsui Mem Hosp, Dept Med, Tokyo 101, Japan Mitsui Mem Hosp Tokyo Japan 101 sui Mem Hosp, Dept Med, Tokyo 101, Japan Asahi Life Fdn, Inst Adult Dis, Dept Gastroenterol, Tokyo, Japan Asahi Life Fdn Tokyo Japan Adult Dis, Dept Gastroenterol, Tokyo, Japan Tokyo Kosei Nenkin Hosp, Dept Med, Tokyo, Japan Tokyo Kosei Nenkin Hosp Tokyo Japan Nenkin Hosp, Dept Med, Tokyo, Japan Kanto Chuo HOsp, Dept Gastroenterol, Tokyo, Japan Kanto Chuo HOsp Tokyo Japan Chuo HOsp, Dept Gastroenterol, Tokyo, Japan Kawasaki Chuo Hosp, Dept Gastroenterol, Kanagawa, Japan Kawasaki Chuo Hosp Kanagawa Japan , Dept Gastroenterol, Kanagawa, Japan Tokyo Metropolitan Geriatr Hosp, Dept Med, Tokyo 173, Japan Tokyo Metropolitan Geriatr Hosp Tokyo Japan 173 pt Med, Tokyo 173, Japan Univ Tokyo, Dept Biostat & Epidemiol, Tokyo, Japan Univ Tokyo Tokyo Japan iv Tokyo, Dept Biostat & Epidemiol, Tokyo, Japan
Titolo Testata:
HEPATOLOGY
fascicolo: 5, volume: 29, anno: 1999,
pagine: 1573 - 1580
SICI:
0270-9139(199905)29:5<1573:PSOITF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; SUSTAINED RESPONSE; VIRUS-INFECTION; NON-A; RANDOMIZED TRIAL; ALPHA-INTERFERON; VIRAL-HEPATITIS; LIVER-DISEASE; ALFA THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Shiratori, Y Univ Tokyo, Dept Internal Med 2, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan Univ Tokyo 7-3-1 Hongo Tokyo Japan 113 ngo, Tokyo 113, Japan
Citazione:
Y. Shiratori et al., "Prospective study of interferon therapy for compensated cirrhotic patientswith chronic hepatitis C by monitoring serum hepatitis C RNA", HEPATOLOGY, 29(5), 1999, pp. 1573-1580

Abstract

Because interferon therapy exhibits low efficacy for cirrhotic patients infected with hepatitis C virus, this prospective study was conducted to determine effective interferon regimens tailored to treatment response by monitoring HCV RNA status. A total of 157 cirrhotic patients were enrolled to receive 9 million units (MU) of interferon three times a week. The HCV RNA values were drawn 8 weeks apart and the patients were randomized to a further16 or 32 weeks of treatment after two sequential findings of negativity for HCV RNA. A total of 73 out of 157 patients (46%) proceeded to randomization to different durations of treatment, 37 short-course and 36 long-course (duration: 38 +/- 8 and 49 +/- 13 weeks; total amount of interferon: 940 +/- 240 and 1130 +/- 390 MU, respectively). The remaining 84 patients withouttwo sequential negative serum HCV RNA determinations received 44.8 +/- 27.4 weeks of interferon (IFN) therapy with total amount of 993 +/- 633 MU. Ofthese 157 patients, sustained virological and biochemical response was shown in 32 (20%) and 37 patients (24%), respectively. Sustained virological and biochemical response rate in the randomized patients was significantly higher than in nonrandomized patients (41% vs. 2%, and 38% vs. 11%; each P <.01). Of the 73 randomized patients, the rate of sustained virological response in patients with long-course treatment (50%) was significantly higherthan that of patients with short-course treatment (32%) (P = .026: log-rank test), and in patients with early disappearance of HCV RNA especially within 8 weeks, in patients with low virus load (less than or equal to 10(6.3)copies/mL) and with HCV 2a, Multivariate analysis revealed that HCV RNA level and subtypes were the most important factors contributing to sustained virological response. Interferon is effective even in cirrhotic patients with low viral load and HCV 2a, but requires a longer course of administration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 18:20:58